Skip to main content
SpringerLink
Log in

Development of a Robust, Rapid and Reliable Tandem Mass Spectrometry Method for the Measurement of Sildenafil, Bosentan and their Major Metabolites

  • ORIGINAL RESEARCH ARTICLE
  • Published:
Indian Journal of Clinical Biochemistry Aims and scope Submit manuscript

Abstract

Pulmonary arterial hypertension (PAH) is a lethal, progressive disease with a complex pathogenesis. Bosentan, a dual endothelin receptor antagonist, and sildenafil, a phosphodiesterase type 5 inhibitor, are used to treat PAH. In this study, we aimed to develop a liquid chromatography-tandem mass spectrometry method (LC–MS/MS) to measure the levels of bosentan, sildenafil, and their active metabolites in patients with PAH. We have developed an LC–MS/MS measurement procedure using a liquid–liquid extraction to measure serum drug concentrations and validated the procedure according to Clinical and Laboratory Standards Institute (CLSI) protocols.

Finally, the validated method was used to measure the levels of sildenafil, bosentan, and their metabolite in pediatric PAH patients. The method was linear in the range of 0.975–1000 ng/ml and 0.76–3125 ng/ml for sildenafil and bosentan, respectively. LOQ values of sildenafil and bosentan were determined as 1.95 and 1.50 ng/ml, respectively. A method for measuring the levels of sildenafil and bosentan was developed that is rapid, robust, inexpensive, and requires a small serum volume. In addition, the validated method measured these drugs’ levels and metabolites in pediatric patients with PAH. The results show that the established method can routinely monitor drug levels.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

  1. Memon HA, Park MH. Pulmonary arterial hypertension in women. Methodist Debakey Cardiovasc J. 2017;13(4):224–37. https://doi.org/10.14797/mdcj-13-4-224.

    Article  PubMed  PubMed Central  Google Scholar 

  2. Chambers E, Wagrowski-Diehl DM, Lu Z, Mazzeo JR. Systematic and comprehensive strategy for reducing matrix effects in LC/MS/MS analyses. J Chromatogr B. 2007;852(1–2):22–34. https://doi.org/10.1016/j.jchromb.2006.12.030.

    Article  CAS  Google Scholar 

  3. Besinque LP. The myth of the stable pulmonary arterial hypertension patient. Am J Manag Care. 2019;25(3):47–52.

    Google Scholar 

  4. Sitbon O, Morrell N. Pathways in pulmonary arterial hypertension: the future is here. Eur Respir Rev. 2012;21(126):321–7. https://doi.org/10.1183/09059180.00004812.

    Article  PubMed  PubMed Central  Google Scholar 

  5. Limoncella S, Lazzaretti C, Paradiso E, D’Alessandro S, Barbagallo F, Pacifico S, et al. Phosphodiesterase (PDE) 5 inhibitors sildenafil, tadalafil and vardenafil impact cAMP-specific PDE8 isoforms-linked second messengers and steroid production in a mouse Leydig tumor cell line. Mol Cell Endocrinol. 2022;542: 111527. https://doi.org/10.1016/j.mce.2021.111527.

    Article  CAS  PubMed  Google Scholar 

  6. Jain MS, Koradia SK. Phosphodiesterase-5 (PDE 5) inhibitors in the treatment of erectile dysfunction: a review. Asian J Pharm Res. 2023;13(1):63–7. https://doi.org/10.52711/2231-5691.2023.00012.

    Article  Google Scholar 

  7. Kuno Y, Iyoda M, Shibata T, Hirai Y, Akizawa T. Sildenafil, a phosphodiesterase type 5 inhibitor, attenuates diabetic nephropathy in non-insulin-dependent Otsuka Long–Evans Tokushima Fatty rats. Br J Pharmacol. 2011;162(6):1389–400. https://doi.org/10.1111/j.1476-5381.2010.01149.x.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  8. Yan H, Yu W. Retinal toxicity of long term overdose of sildenafil citrate: a case report. Am J Ophthalmol Case Rep. 2023;29: 101761. https://doi.org/10.1016/j.ajoc.2022.101761.

    Article  PubMed  Google Scholar 

  9. Sheweita SA, Alian DME, Haroun M, Nounou MI, Patel A, El-Khordagui L. Chitosan nanoparticles alleviated the adverse effects of sildenafil on the oxidative stress markers and antioxidant enzyme activities in rats. Oxid Med Cell Longev. 2023. https://doi.org/10.1155/2023/9944985.

    Article  PubMed  PubMed Central  Google Scholar 

  10. Tang P-F, Zheng X, Hu X-X, Yang C-C, Chen Z, Qian J-C, et al. Functional measurement of CYP2C9 and CYP3A4 allelic polymorphism on sildenafil metabolism. Drug Des Develop Ther. 2020. https://doi.org/10.2147/DDDT.S268796.

    Article  Google Scholar 

  11. Kuntz M, Leiva-Juarez MM, Luthra S. Systematic review of randomized controlled trials of endothelin receptor antagonists for pulmonary arterial hypertension. Lung. 2016;194:723–32. https://doi.org/10.1007/s00408-016-9928-6.

    Article  CAS  PubMed  Google Scholar 

  12. Roberts KE, Preston IR. Safety and tolerability of bosentan in the management of pulmonary arterial hypertension. Drug Des Develop Ther. 2009. https://doi.org/10.2147/DDDT.S3786.

    Article  Google Scholar 

  13. Dingemanse J, van Giersbergen PLJC. Clinical pharmacology of bosentan, a dual endothelin receptor antagonist. Clin Pharm. 2004;43(15):1089–115.

    Article  CAS  Google Scholar 

  14. Dingemanse J, Bodin F, Weidekamm E, Kutz K, van Giersbergen P. Influence of food intake and formulation on the pharmacokinetics and metabolism of bosentan, a dual endothelin receptor antagonist. J Clin Pharmacol. 2002;42(3):283–9. https://doi.org/10.1177/00912700222011300.

    Article  CAS  PubMed  Google Scholar 

  15. Weber C, Gasser R, Hopfgartner GJDM. Disposition Absorption, excretion, and metabolism of the endothelin receptor antagonist bosentan in healthy male subjects. Drug Metab Dispos. 1999;27(7):810–5.

    CAS  PubMed  Google Scholar 

  16. Ausó E, Gómez-Vicente V, Esquiva G. Visual side effects linked to sildenafil consumption: an update. Biomedicines. 2021;9(3):291. https://doi.org/10.3390/biomedicines9030291.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  17. Fagelman E, Fagelman A, Shabsigh R. Efficacy, safety, and use of sildenafil in urologic practice. Urology. 2001;57(6):1141–4. https://doi.org/10.1016/S0090-4295(01)00984-0.

    Article  CAS  PubMed  Google Scholar 

  18. O’Callaghan D, Gaine SP. Bosentan: a novel agent for the treatment of pulmonary arterial hypertension. Int J Clin Pract. 2004;58(1):69–73. https://doi.org/10.1111/j.1368-5031.2004.0098.x.

    Article  CAS  PubMed  Google Scholar 

  19. Siehr SL, McCarthy EK, Ogawa MT, Feinstein JA. Reported sildenafil side effects in pediatric pulmonary hypertension patients. Front Pediatr. 2015;3:12. https://doi.org/10.3389/fped.2015.00012.

    Article  PubMed  PubMed Central  Google Scholar 

  20. Fu W, Chen P, Xia J, Fu L, Shen Y, He W, et al. Efficacy and safety of endothelin receptor antagonists combined with phosphodiesterase 5 inhibitor in the treatment of pulmonary arterial hypertension: a network meta-analysis. Chin J Tuber Resp Dis. 2022;45(2):158–70. https://doi.org/10.3760/cma.j.cn112147-20210707-00473.

    Article  CAS  Google Scholar 

  21. Maneenil G, Talek S, Thatrimontrichai A, Janjindamai W, Dissaneevate S. The use of bosentan and sildenafil as rescue therapy in persistent pulmonary hypertension of the newborn: a single center’s experience. Prog Pediatr Cardiol. 2022;67: 101575. https://doi.org/10.1016/j.ppedcard.2022.101575.

    Article  Google Scholar 

  22. Wang R, Wei M, Wang J, Huang X, Yan Q, Wang S, et al. A network meta-analysis of the efficacy and safety of targeted drug combinations in the treatment of pulmonary arterial hypertension. LWW. 2023. https://doi.org/10.1097/CD9.0000000000000105.

    Article  Google Scholar 

  23. Eerkes A, Addison T, Naidong W. Simultaneous assay of sildenafil and desmethylsildenafil in human plasma using liquid chromatography–tandem mass spectrometry on silica column with aqueous–organic mobile phase. J Chromatogr B. 2002;768(2):277–84. https://doi.org/10.1016/S1570-0232(01)00602-X.

    Article  CAS  Google Scholar 

  24. Lausecker B, Hopfgartner G. Determination of an endothelin receptor antagonist in human plasma by narrow-bore liquid chromatography and ionspray tandem mass spectrometry. J Chromatogr A. 1995;712(1):75–83. https://doi.org/10.1016/0021-9673(95)00331-G.

    Article  CAS  PubMed  Google Scholar 

  25. Tanaka S, Uchida S, Hakamata A, Miyakawa S, Odagiri K, Inui N, et al. Simultaneous LC-MS analysis of plasma concentrations of sildenafil, tadalafil, bosentan, ambrisentan, and macitentan in patients with pulmonary arterial hypertension. Die Pharm Int J Pharm Sci. 2020;75(6):236–9. https://doi.org/10.1691/ph.2020.0021.

    Article  CAS  Google Scholar 

  26. Rashid J, Ahsan F. A highly sensitive LC–MS/MS method for concurrent determination of sildenafil and rosiglitazone in rat plasma. J Pharm Biomed Anal. 2016;129:21–7. https://doi.org/10.1016/j.jpba.2016.06.022.

    Article  CAS  PubMed  Google Scholar 

  27. Qiu X, Zhao J, Wang Z, Xu Z, Xu R. Simultaneous determination of bosentan and glimepiride in human plasma by ultra performance liquid chromatography tandem mass spectrometry and its application to a pharmacokinetic study. J Pharm Biomed Anal. 2014;95:207–12. https://doi.org/10.1016/j.jpba.2014.03.011.

    Article  CAS  PubMed  Google Scholar 

  28. Liew KB, Loh GOK, Tan YTF, Peh KK. Simultaneous quantification of sildenafil and N-desmethyl sildenafil in human plasma by UFLC coupled with ESI-MS/MS and pharmacokinetic and bioequivalence studies in Malay population. Biomed Chromatogr. 2015;29(6):953–60. https://doi.org/10.1002/bmc.3378.

    Article  CAS  PubMed  Google Scholar 

  29. Challa BR, Awen BZ, Chandu BR, Khagga M, Bannoth CK, Kanala K, et al. Sildenafil and N-desmethyl sildenafil quantification in human plasma by HPLC coupled with ESI-MS/MS detection: application to bioequivalence study. Anal Methods. 2010;2(8):1043–50. https://doi.org/10.1039/C0AY00062K.

    Article  CAS  Google Scholar 

  30. Yokoyama Y, Tomatsuri M, Hayashi H, Hirai K, Ono Y, Yamada Y, et al. Simultaneous microdetermination of bosentan, ambrisentan, sildenafil, and tadalafil in plasma using liquid chromatography/tandem mass spectrometry for pediatric patients with pulmonary arterial hypertension. J Pharm Biomed Anal. 2014;89:227–32. https://doi.org/10.1016/j.jpba.2013.11.007.

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgements

This research was supported by Selcuk University Scientific Research Projects Coordination (Project Number 17202067). The authors would like to thank Selcuk University for funding this project.

Author information

Authors and Affiliations

  1. Department of Medical Biochemistry, Faculty of Medicine, Selcuk University, 42130, Konya, Turkey

    Mohammad Ahmad Bik, Duygu Eryavuz Onmaz, Fadime Karaman, Sedat Abusoglu, Abdullah Sivrikaya & Ali Unlu

  2. National Diabetes Center for Treatment and Research, Mustansiriyah University, 14022, Baghdad, Iraq

    Karam Mazin Kamil Gharab

Authors
  1. Mohammad Ahmad Bik
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Duygu Eryavuz Onmaz
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Karam Mazin Kamil Gharab
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Fadime Karaman
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Sedat Abusoglu
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Abdullah Sivrikaya
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Ali Unlu
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Mohammad Ahmad Bik.

Ethics declarations

Conflict of interest

The authors declare that they have no conflict of interest relevant to the content of this manuscript.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Bik, M.A., Onmaz, D.E., Gharab, K.M.K. et al. Development of a Robust, Rapid and Reliable Tandem Mass Spectrometry Method for the Measurement of Sildenafil, Bosentan and their Major Metabolites. Ind J Clin Biochem (2024). https://doi.org/10.1007/s12291-024-01215-x

Download citation

  • Received:

  • Accepted:

  • Published:

  • DOI: https://doi.org/10.1007/s12291-024-01215-x

Keywords

Search

Navigation